FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability−high (MSI-H) or mismatch repair−deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single-agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic